Awards Nomination 20+ Million Readerbase
PMC/PubMed Indexed Articles

Statistical considerations in biosimilar assessment using biosimilarity index

In-vitro Release of Rapamycin from a Thermosensitive Polymer for the Inhibition of Vascular Smooth Muscle Cell Proliferation

View More »

Google Scholar citation report
Citations : 4363

Journal of Bioequivalence & Bioavailability received 4363 citations as per Google Scholar report

Flyer image
Journal of Bioequivalence & Bioavailability peer review process verified at publons
Flyer image
Indexed In
  • Academic Journals Database
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Ulrich's Periodicals Directory
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
View More
Useful Links
Share This Page
Journal Flyer
Flyer image
Open Access Journals
View More

Joel Posener

Joel Posener

Early Clinical Development at AstraZeneca Neuroscience Innovative Medicines (iMed), USA

Biography
Joel Posener, MD, is the Head of Clinical Development in the AstraZeneca Neuroscience Innovative Medicines unit, which is responsible for the company's discovery and early development efforts in psychiatry, neurology and pain. Dr. Posener is a board certified psychiatrist with more than 10 years of experience in each of academic medicine and the pharmaceutical industry. He has broad experience in drug development, encompassing Phases 1-3, clinical pharmacology, translational medicine, and multiple indications in psychiatry and neurology, including schizophrenia (psychosis and cognitive impairment), depression, bipolar disorder, Alzheimer Disease, Parkinson's Disease (symptomatic and disease modification), other movement disorders, pain (various types), and orphan diseases. In addition to his primary responsibility at AstraZeneca, Dr. Posener serves on the faculty at Temple University School of Medicine, where he is Clinical Professor of Psychiatry.
Research Interest
Psychiatry NeuroScience